Basic and clinical aspects of non-neuronal acetylcholine: Biological and clinical significance of non-canonical ligands of epithelial nicotinic acetylcholine receptors

Journal of Pharmacological Sciences

Volumn 106, Issue 2, 2008, Pages 174-179

  Grando, Sergei A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Keratinocyte; Nicotinic acetylcholine receptor; Nitrosoamine; Non neuronal cholinergic system; SLURP 1; SLURP 2

Indexed keywords

ACETYLCHOLINE; CARCINOGEN; NICOTINIC RECEPTOR; NITROSAMINE; PROTEIN DERIVATIVE; SECRETED MAMMALIAN LYSINE 6 UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR RELATED PROTEIN 1; SECRETED MAMMALIAN LYSINE 6 UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR RELATED PROTEIN 2; UNCLASSIFIED DRUG;

APOPTOSIS; BIOLOGICAL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLINERGIC SYSTEM; EPITHELIUM; HUMAN; KERATINOCYTE; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; SHORT SURVEY; TOBACCO;

EID: 40549109577     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FM0070087     Document Type: Short Survey

References (35)

1. Grando SA, Kawashima K, Kirkpatrick CJ, Wessler I. Recent progress in understanding the non-neuronal cholinergic system in humans. Life Sci. 2007;80:2181-2185.
2. Grando SA, Pittelkow MR, Schallreuter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. J Invest Dermatol. 2006;126:1948-1965.
3. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest. 2003;111:81-90.
4. Guerin MR, Jenkins RA, Tomkins BA, Eisenberg SE. The chemistry of environmental tobacco smoke: composition and measurement. Boca Raton: Lewis Publishers; 1992.
5. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis. 1988;9:875-884.
6. Jull BA, Plummer HK 3rd, Schuller HM. Nicotinic receptormediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J Cancer Res Clin Oncol. 2001;127:707-717.
7. Schuller HM, Plummer HK 3rd, Jull BA. Receptor-mediated effects of nicotine and its nitrosated derivative NNK on pulmonary neuroendocrine cells. Anat Rec. 2003;270A:51-58.
8. Schuller HM, Jull BA, Sheppard BJ, Plummer HK. Interaction of tobacco-specific toxicants with the neuronal α7 nicotinic acetylcholine receptor and its associated mitogenic signal transduction pathway: potential role in lung carcinogenesis and pediatric lung disorders. Eur J Pharmacol. 2000;393:265-277.
9. Schuller HM, Park PG, Orloff M. N'-Nitrosonornicotine (NNN) is a selective ligand for epibatidine-sensitive nicotinic acetylcholine receptors in human lung adenocarcinoma. Proc Am Assoc Cancer Res. 1997;38:65.
10. Schuller HM, Orloff M. Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochem Pharmacol. 1998;55:1377-1384.
11. Arredondo J, Chernyavsky AI, Grando SA. The nicotinic receptor antagonists abolish pathobiologic effects of tobaccoderived nitrosamines on BEP2D cells. J Cancer Res Clin Oncol. 2006;132:653-663.
12. Arredondo J, Chernyavsky AI, Grando SA. Nicotinic receptors mediate tumorigenic action of tobacco-derived nitrosamines on immortalized oral epithelial cells. Cancer Biol Ther. 2006;5: 511-517.
13. Jin Z, Gao F, Flagg T, Deng X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem. 2004;279:40209-402019.
14. Conti-Tronconi BM, McLane KE, Raftery MA, Grando SA, Protti MP. The nicotinic acetylcholine receptor: structure and autoimmune pathology. Crit Rev Biochem Mol Biol. 1994;29: 69-123.
15. Sybert VP, Dale BA, Holbrook KA. Palmar-plantar keratoderma. A clinical, ultrastructural, and biochemical study. J Am Acad Dermatol. 1988;18:75-86.
16. Fischer J, Bouadjar B, Heilig R, Huber M, Lefevre C, Jobard F, et al. Mutations in the gene encoding SLURP-1 in Mal de Meleda. Hum Mol Genet. 2001;10:875-880.
17. Tsuji H, Okamoto K, Matsuzaka Y, Iizuka H, Tamiya G, Inoko H. SLURP-2, a novel member of the human Ly-6 superfamily that is up-regulated in psoriasis vulgaris. Genomics. 2003;81: 26-33.
18. Adermann K, Wattler F, Wattler S, Heine G, Meyer M, Forssmann WG, et al. Structural and phylogenetic characterization of human SLURP-1, the first secreted mammalian member of the Ly-6/uPAR protein superfamily. Protein Sci.1999;8:810-819.
19. Mastrangeli R, Donini S, Kelton CA, He C, Bressan A, Milazzo F, et al. ARS Component B: structural characterization, tissue expression and regulation of the gene and protein (SLURP-1) associated with Mal de Meleda. Eur J Dermatol. 2003;13:560-570.
20. Arredondo J, Chernyavsky AI, Webber RJ, Grando SA. Biological effects of SLURP-1 on human keratinocytes. J Invest Dermatol. 2005;125:1236-1241.
21. Favre B, Plantard L, Aeschbach L, Brakch N, Christen-Zaech S, de Viragh PA, et al. SLURP1 is a late marker of epidermal differentiation and is absent in Mal de Meleda. J Invest Dermatol. 2007;127:301-308.
22. Arredondo J, Chernyavsky AI, Grando SA. SLURP-1 and -2 in normal, immortalized and malignant oral keratinocytes. Life Sci. 2007;80:2243-2247.
23. Arredondo J, Chernyavsky AI, Jolkovsky DL, Webber RJ, Grando SA. SLURP-2: A novel cholinergic signaling peptide in human mucocutaneous epithelium. J Cell Physiol. 2006;208: 238-245.
24. Kawashima K, Yoshikawa K, Fujii YX, Moriwaki Y, Misawa H. Expression and function of genes encoding cholinergic components in murine immune cells. Life Sci. 2007;80:2314-2319.
25. Moriwaki Y, Yoshikawa K, Fukuda H, Fujii YX, Misawa H, Kawashima K. Immune system expression of SLURP-1 and SLURP-2, two endogenous nicotinic acetylcholine receptor ligands. Life Sci. 2007;80:2365-2368.
26. Chimienti F, Hogg RC, Plantard L, Lehmann C, Brakch N, Fischer J, et al. Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda. Hum Mol Genet. 2003;2:3017-3024.
27. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421:384-388.
28. Ribeiro U Jr, Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg. 1996;83:1174-1185.
29. Mozzillo N, Nunziata CA, Caraco C, Fazioli F, Botti G. Malignant melanoma developing in an area of hereditary palmoplantar keratoderma (Mal de Meleda). J Surg Oncol. 2003;84:229-233.
30. Arredondo J, Chernyavsky AI, Grando SA. Overexpression of SLURP-1 and -2 alleviates the tumorigenic action of tobaccoderived nitrosamine on immortalized oral epithelial cells. Biochem Pharmacol. 2007;74:1315-1319.
31. Arredondo J, Chernyavsky AI, Marubio LM, Beaudet AL, Jolkovsky DL, Pinkerton KE, et al. Receptor-mediated tobacco toxicity: Regulation of gene expression through α3β2 nicotinic receptor in oral epithelial cells. Am J Pathol. 2005;166:597-613.
32. Arredondo J, Nguyen VT, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA. A receptor-mediated mechanism of nicotine toxicity in oral keratinocytes. Lab Invest. 2001;81: 1653-1668.
33. Vayssier M, Banzet N, Francois D, Bellmann K, Polla BS. Tobacco smoke induces both apoptosis and necrosis in mammalian cells: differential effects of HSP70. Am J Physiol. 1998;275:L771-L779.
34. D'Agostini F, Balansky RM, Izzotti A, Lubet RA, Kelloff GJ, De Flora S. Modulation of apoptosis by cigarette smoke and cancer chemopreventive agents in the respiratory tract of rats. Carcinogenesis. 2001;22:375-380.
35. Minna JD. Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. J Clin Invest. 2003;111:31-33.